Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial

Fig. 3

Symptom severity outcomes (SAC-TDI (a), E-RS (b), % rescue salbutamol-free days (c)). CI, confidence interval; COPD, chronic obstructive pulmonary disease; E-RS, Evaluating Respiratory Symptoms-COPD; LS, least squares; SAC-TDI, self-administered computerised Transition Dyspnoea Index; SAL, salmeterol; UMEC, umeclidinium; VI, vilanterol

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us